Akèy › Kansè Vezik ki pa envazif miskilè › Ohio
Etid klinik pou Kansè Vezik ki pa envazif miskilè nan Ohio
13 etid pou Kansè Vezik ki pa envazif miskilè ap chèche patisipan nan sit nan Ohio.
Vil nan Ohio
Tèks ofisyèl etid la (Anglè)
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07000084A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- TriState Urologic Services PSC Inc. dba The Urology Group ( Site 0122), Cincinnati
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06833073Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
- The James at Brain and Spine Hospital (OSU), Columbus
- Oregon Urology Institute, Springfield
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06995677A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
- Dayton Physicians Network Urology, Centerville
- Central Ohio Urology Group, Gahanna
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06919965Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance
- University Hospitals Cleveland Medical Center, Cleveland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT05796375Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Cleveland Clinic Main Campus, Cleveland, Cleveland
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 24, 2026 · NCT05951179FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Cincinnati Medical Center (UCMC), Cincinnati
- The Ohio State University (OSU), Columbus
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT05614739LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
- University of Cincinnati Medical Center, Cincinnati
- Central Ohio Urology Group, Gahanna
- Clinical Research Solutions - Helios Clinical Research, Middleburg Heights
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 7, 2026 · NCT04752722Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- The Ohio State University, Columbus
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 31, 2026 · NCT07225127A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
- The Ohio State University, Columbus
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou May 27, 2026 · NCT05710848Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
- Ohio State University Comprehensive Cancer Center, Columbus
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Mar 16, 2026 · NCT07474519Blue Light Cystoscopy With Cysview® Registry
- Ohio State University Wexner Medical Center, Columbus
- Ohio State University, Columbus
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Dec 18, 2025 · NCT02660645Intravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
- Site 02-017 - Central Ohio Urology Group, Gahanna
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Nov 24, 2025 · NCT03945162Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.